Donate now, support IFFGD

My Cart | Register | Sign In

Header Image


Elobixibat is a first-in-class compound under investigation for treatment of chronic idiopathic constipation (CIC), and for irritable bowel syndrome with constipation (IBS-C). It works by reducing bile acid absorption in the small intestine. This stimulates bowel movements by increasing fluid secretions and motility in the colon.

In Phase 2b clinical trials, elobixibat (formerly A3309) has been evaluated in patients in the U.S. and Europe for the treatment of CIC. The studies demonstrated clinically meaningful, statistically significant, and dose-dependent improvements. These included increased stool frequency and improved constipation-related symptoms such as straining, stool consistency, and bloating maintained over 8 weeks of treatment.

May 2, 2013 — Elobixibat has entered Phase 3 trials for the CIC indication. There will be two studies which will be conducted at close to 200 sites around the world. For more information, visit the trial information on


Last modified on June 14, 2013 at 03:49:40 PM